Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note ...

Merck KGaA, Darmstadt, Germany, and Bio-Techne announced they entered into a definitive agreement under which Merck KGaA will acquire Bio-Techne for $73 per share in cash. The transaction represents a ...

Bio-Techne, a Minneapolis-based provider of life sciences tools, reagents, and diagnostic products, has announced that its shareholders have approved the company’s proposed acquisition by Merck KGaA, ...

I cover both Merck (MRK) and Merck KGaA (MKGAF) (which I hereafter will call "Merck", because this article is about the latter), but the latter is more of a focus for me given what's been going on in ...

German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade, as it looks to strengthen its life sciences business.

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne ...